MCPyV was more commonly found in adults than in children. Presence in the upper respiratory tract may be a general property of human PyVs.”
“With increasing environmental awareness, evaluating the potential of biopolymers as a substitute for traditional materials has been of great interest. Crystallization kinetics provides fundamental knowledge required for evaluation, playing HDAC inhibitor vital role in determining the final properties of the product. In this study, the isothermal and nonisothermal crystallization kinetics of poly(epsilon-caprolactone) (PCL) were investigated with the help of various models. The Avrami model best described the isothermal crystallization

kinetics, suggesting three-dimensional spherulitic growth, which was in agreement with the morphology studies; whereas the Liu model fit well under nonisothermal crystallization conditions. The failure of the Kissinger model to determine the activation energy was overcome with the Friedman model. The kinetic crystallizability determined by the Ziabacki model indicated a higher crystallization ability of PCL at lower cooling rates. (C) 2011 PFTα supplier Wiley Periodicals, Inc. J Appl Polym Sci, 2012″
“Background: The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is immunogenic, has a clinically acceptable safety profile, and prevents incident and persistent

HPV-16/18 infection and cervical precancerous lesions. This study (NCT00552279) evaluated the vaccine when administered according to an alternative dosing schedule (0-1-12 months) compared with the standard dosing schedule (0-1-6 months).

Methods: The study was of randomized open design and was conducted at multiple centers in Europe. Healthy women aged 15 to 25 years were randomized (1: 1) to receive HPV-16/18 vaccine according to the standard schedule at months 0, 1, and 6 (n = 401) or an alternative schedule at months 0, 1, and 12 (n = 403). HPV-16 and -18 antibodies were measured by enzyme-linked immunosorbent assay at months

0, 2, and 7 or 13 (depending on group); noninferiority evaluation was performed sequentially for seroconversion rates and geometric mean antibody titers. Primary analysis of immunogenicity was based on the according-to-protocol cohort. Vaccine safety and reactogenicity check details were assessed on the total vaccinated cohort.

Results: Predefined noninferiority criteria were met 1 month after the third vaccine dose when the HPV-16/18 vaccine was administered according to the 0-1-12 month schedule compared with the 0-1-6 month schedule in terms of seroconversion rates for HPV-16 (100% and 100%) and HPV-18 (99.7% and 100%) and geometric mean antibody titers for HPV-16 (11884.7 and 10311.9 ELISA units/mL) and HPV-18 (4501.3 and 3963.6 ELISA units/mL), respectively. The HPV-16/18 vaccine had a clinically acceptable safety profile when administered according to either schedule.